Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis

17Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Objective: To evaluate salivary interleukin (IL)-1β levels in patients with psoriasis, before and after treatment with tumour necrosis factor (TNF)-α inhibitors. Methods: In this pilot study, salivary secretions were collected from patients with psoriasis and untreated healthy control subjects at baseline, and from patients after 12 weeks’ treatment with TNF-α inhibitors. IL-1β levels were determined in saliva samples via enzyme-linked immunosorbent assays, undertaken before and after TNF-α inhibitor treatment. Psoriasis-specific analysis of disease severity and activity were also undertaken. Results: At baseline, patients (n = 25) had significantly higher salivary IL1β levels than controls (n = 20). In patients with psoriasis, TNF-α inhibitor treatment resulted in significantly reduced IL1β levels compared with baseline, but IL1β levels remained significantly higher than in control subjects even after treatment. There was a positive correlation between IL-1β levels, psoriasis activity and disease index score after TNF-α inhibitor treatment. Conclusion: Saliva is a valid noninvasive tool for monitoring inflammation in psoriasis. TNF-α inhibitor treatments appear to interfere with the oral inflammatory process in patients with psoriasis.

Cite

CITATION STYLE

APA

Ganzetti, G., Campanati, A., Santarelli, A., Sartini, D., Molinelli, E., Brisigotti, V., … Offidani, A. (2016). Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis. Journal of International Medical Research, 44(1_suppl), 10–14. https://doi.org/10.1177/0300060515598902

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free